Bone Marrow Phospho-STAT5 Expression in Non-CML Chronic Myeloproliferative Disorders Correlates With JAK2 V617F Mutation and Provides Evidence of In Vivo JAK2 Activation-Reference-Cited by-同舟云学术

Bone Marrow Phospho-STAT5 Expression in Non-CML Chronic Myeloproliferative Disorders Correlates With JAK2 V617F Mutation and Provides Evidence of In Vivo JAK2 Activation

Published:2007-02 Issue:2 Volume:31 Page:233-239
ISSN:0147-5185
Container-title:The American Journal of Surgical Pathology
language:en
Short-container-title:The American Journal of Surgical Pathology

Author:

Aboudola Samer,Murugesan Guruanthan,Szpurka Hadrian,Ramsingh Giri,Zhao Xiaoxian,Prescott Nichole,Tubbs Raymond R.,Maciejewski Jaroslaw P.,Hsi Eric D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Reference35 articles.

1. Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

3. Delineation and Mapping of Stat5 Isoforms Activated by Granulocyte Colony-Stimulating Factor in Myeloid Cells

4. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations

5. Roles and Regulation of Stat Family Transcription Factors in Human Breast Cancer

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells;BMC Cancer;2022-12-02

2. Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cells;2021-05-07

3. The JAK2 mutation;Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A;2021

4. A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays;Leukemia & Lymphoma;2020-08-15

5. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy;Virchows Archiv;2018-08-21